Indeed, as devoid of extracellular ligand-binding domain, ErbB380kDa is untargeted by ErbB3 therapeutic antibodies currently under Phase I or II clinical assays in various tumours, we have tested so far (unpublished data). Here, ERBB3 is linked to neoplasm.